Fig. 2From: A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaPercent change in hemoglobin level from baseline to end of cycle 4 (week 12). Values shown are for evaluable patients in study part B who received 10 mg/kg LY2787106 weekly (QW) without and with oral iron (cohorts B1 [n = 6] and B2 [n = 7], respectively). Only patients with a baseline and postbaseline result are included; for patients who did not reach week 12, their final assessment was usedBack to article page